| Stereochemistry | ACHIRAL |
| Molecular Formula | C2H7N5 |
| Molecular Weight | 101.1105 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC(N)=N
InChI
InChIKey=XNCOSPRUTUOJCJ-UHFFFAOYSA-N
InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)
| Molecular Formula | C2H7N5 |
| Molecular Weight | 101.1105 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Biguanide has been investigated for the treatment of Diabetes Mellitus. The term "biguanidine" often refers specifically to a class of drugs that have a broad range of medical indications. Besides recent experiments have shown that biguanide could be a modifiable pharmacophore for the synthesis of therapeutic cysteinyl cathepsins inhibitors with a wide range of potencies and specificities. It is known that excessive activities of cysteinyl cathepsins contribute to the progress of many diseases.